Karel, D.; Valburg, C.; Woddor, N.; Nava, V.E.; Aggarwal, A. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape. Curr. Oncol.2024, 31, 1971-1993.
Karel, D.; Valburg, C.; Woddor, N.; Nava, V.E.; Aggarwal, A. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape. Curr. Oncol. 2024, 31, 1971-1993.
Karel, D.; Valburg, C.; Woddor, N.; Nava, V.E.; Aggarwal, A. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape. Curr. Oncol.2024, 31, 1971-1993.
Karel, D.; Valburg, C.; Woddor, N.; Nava, V.E.; Aggarwal, A. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape. Curr. Oncol. 2024, 31, 1971-1993.
Abstract
Myelodysplastic neoplasm (MDS) is a heterogenous clonal disorder of hemopoietic stem cells charac-terized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of pro-gression to Acute Myeloid Leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently prognostication and treatment are determined by cytogenetic and molecular data. Specific genetic abnormalities such as 5q deletion (del 5q), TP53 inactivation and SF3B1 mutation, are increasingly associated with disease phenotype and outcomes, as reflected in the recently updated 5th edition of the World Health Organization Classification of Hematolymphoid Tumors (WHO5) and International Consensus Classification 2022 (ICC 2022) classifications. Treatments are in-creasingly being tailored for patient specific phenotypes, and trials exploring the efficacy of targeted treatments are ongoing in this era of precision medicine.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
